Knight Therapeutics | GUD - Cash And Equivalent


Knight Therapeutics reported CAD76.45M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 18.67M 1.81M Dec/2025
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Canopy Growth CAD 364.68M 6.64M Mar/2026
Cronos Group USD 791.79M 7.62M Dec/2025
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Moderna USD 1.91B 687M Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Organigram Holdings CAD 4.29M 3.28M Mar/2026
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Tilray USD 264.83M 43.16M Jun/2025
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026